You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

878 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria
Exceptional Access Program
    venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria
Aug 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria
Sep 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
Aug 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Genitourinary, 
Penile
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jul 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus
Intent: Adjuvant, Palliative
Apr 2023

Pages